Dofetilide Capsule
Product Images NDC 0904-7522

9 FDA label images from Major Pharmaceuticals · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Dofetilide (NDC 0904-7522). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Major Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Dofetilide 01)

Chemical Structure (Dofetilide 01)
Chemical structure of the active ingredient Dofetilide, showing its molecular composition and bonding arrangement.*
FDA Label Image

Figure 1 (Dofetilide 02)

Figure 1 (Dofetilide 02)
A line graph depicting the mean change from baseline QTc interval (in milliseconds) versus mean plasma dofetilide concentration (ng/mL) at Day 1 and Day 23 (steady state). The graph uses squares for Day 1 data points and diamonds for Day 23, with lines showing trends for each day.*
FDA Label Image

Figure 2 (Dofetilide 03)

Figure 2 (Dofetilide 03)
Bar and dot plot comparing the change in QTc interval from baseline and the probability of remaining in normal sinus rhythm (NSR) at 6 months for placebo and three doses of Dofetilide capsules: 125 mcg BID, 250 mcg BID, and 500 mcg BID. The left Y-axis shows QTc change in milliseconds with 95% confidence intervals, and the right Y-axis shows the probability of remaining in NSR percentage with 95% confidence intervals.*
FDA Label Image

Figure 3 (Dofetilide 04)

Figure 3 (Dofetilide 04)
A Kaplan-Meier survival curve chart showing the probability of remaining in normal sinus rhythm (NSR) over time (months) for patients treated with three dosages of dofetilide (125 mcg BID, 250 mcg BID, 500 mcg BID) compared to placebo. The chart includes p-values from Log Rank Tests for each dosage group versus placebo.*
FDA Label Image

Figure 4 (Dofetilide 05)

Figure 4 (Dofetilide 05)
A Kaplan-Meier survival curve graph showing the probability of remaining in NSR (normal sinus rhythm) over 12 months. The graph compares four groups: placebo and three doses of dofetilide (125 mcg BID, 250 mcg BID, and 500 mcg BID). Probability decreases over time, with higher doses of dofetilide maintaining higher probabilities of NSR. A p-value log rank test box indicates statistical significance for all dofetilide doses compared to placebo.*
FDA Label Image

Figure (Dofetilide 06)

Figure (Dofetilide 06)
A flowchart outlining the dosing adjustment process for Dofetilide capsules based on patient telemetry, baseline QTc or QT intervals, and calculated creatinine clearance (Clcr). It includes specific dosing recommendations and criteria for contraindication and dose adjustment after monitoring QTc or QT changes post dose.*
FDA Label Image

125mcg Carton Label (Cfb67967 E633 9056 6d99 C42ec7905f2e 02)

FDA Label Image

250mcg Carton Label (Cfb67967 E633 9056 6d99 C42ec7905f2e 01)

FDA Label Image

500mcg Carton Label (Cfb67967 E633 9056 6d99 C42ec7905f2e 00)

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.